A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
NCT02978235 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11
Last updated 2024-09-05
Summary
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
Conditions
- Multiple Myeloma
- NonHodgkin Lymphoma
Interventions
- DRUG
-
TAS4464
Intravenous (IV) Infusion
Sponsors & Collaborators
-
Taiho Oncology, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-03-01
- Primary Completion
- 2018-02-01
- Completion
- 2018-02-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
NCT00458159 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
NCT02244463 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
NCT02184897 ·Status: UNKNOWN ·Phase: NA
-
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
NCT02323113 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
NCT01011283 ·Status: TERMINATED ·Phase: PHASE4
-
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
NCT00113321 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome
NCT00676728 ·Status: TERMINATED ·Phase: PHASE1
-
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
NCT00807677 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes
NCT00828802 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
NCT04896112 ·Status: WITHDRAWN ·Phase: PHASE1
-
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
NCT03816319 ·Status: SUSPENDED ·Phase: PHASE1
-
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
NCT00004009 ·Status: COMPLETED ·Phase: PHASE1
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Ascending Dose of BMS-911543
NCT01236352 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
NCT02238925 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
NCT00619099 ·Status: COMPLETED ·Phase: PHASE2
-
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma
NCT04582539 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT01687400 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
NCT02093429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
NCT05426798 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
NCT01177540 ·Status: TERMINATED ·Phase: PHASE2
-
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02029417 ·Status: TERMINATED ·Phase: PHASE2
-
Sorafenib in Myelodysplastic Syndrome
NCT00510289 ·Status: TERMINATED ·Phase: PHASE2
-
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
NCT00005845 ·Status: COMPLETED ·Phase: PHASE1
-
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
NCT00630994 ·Status: TERMINATED ·Phase: PHASE2